Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?
The DOI matches its Crossref record; 265 of the 265 references it cites were found in a registry or an index.
Abstract
It is generally thought that many drug molecules are transported across biological membranes via passive diffusion at a rate related to their lipophilicity. However, the types of biophysical forces involved in the interaction of drugs with lipid membranes are no different from those involved in their interaction with proteins, and so arguments based on lipophilicity could also be applied to drug uptake by membrane transporters or carriers. In this article, we discuss the evidence supporting the idea that rather than being an exception, carrier-mediated and active uptake of drugs may be more common than is usually assumed - including a summary of specific cases in which drugs are known to be taken up into cells via defined carriers - and consider the implications for drug discovery and development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Note that despite a widespread assumption that lipophilicity or log P is sufficient to account for drug distribution this is not in fact the case, as there are hundreds of natural transporters that drugs can use (e.g. [18,1714]).”
In the citing paper
“(Note that liophilicity per se may not be relevant, as drugs require carriers to cross membranes [18], and promiscuity and off-target effects increase with lipophilicity [1679].)”
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
CHEMIOSMOTIC COUPLING IN OXIDATIVE AND PHOTOSYNTHETIC PHOSPHORYLATION
MITCHELL, P. (1966) · Biological Reviews · doi:10.1111/j.1469-185x.1966.tb01501.x · Cited by 3,663
A gene atlas of the mouse and human protein-encoding transcriptomes
Su, A. I., Wiltshire, T., Batalov, S., Lapp, H., Ching, K. A., Block, D., Zhang, J., Soden, R., Hayakawa, M., Kreiman, G., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400782101 · Cited by 3,475
Hucka, M., Finney, A., Sauro, H. M., Bolouri, H., Doyle, J. C., Kitano, H., Arkin, A. P., Bornstein, B. J., Bray, D., Cornish-Bowden, A., et al. (2003) · Bioinformatics · doi:10.1093/bioinformatics/btg015 · Cited by 3,060
Drugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512 · cited 1×
“, do not obey the Ro5 (for example, most antibacterial”
BackgroundThe influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403 · cited 1×
“This is because many of the recent trends in molecular drug design and development have been towards increased lipophilicity, leading to a greater likelihood of both a lack of selectivity and of attritio”
BackgroundThe Membrane Actions of Anesthetics and Tranquilizers
Seeman, P. (1972) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06931-5 · Cited by 2,246
Abraham, M. H. (1993) · Chemical Society Reviews · doi:10.1039/cs9932200073 · Cited by 1,968
Osmotic Stress Signaling and Osmoadaptation in Yeasts
Hohmann, S. (2002) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.66.2.300-372.2002 · Cited by 1,767
Research works printed but not linked: 1
- Jain, M. K. The Bimolecular Lipid Membrane. (Van Nostrand Reinhold, New York, 1972).
Cited by
Items 101–200 of 479
Brain drug targeting: a computational approach for overcoming blood–brain barrier
Mehdipour, A. R., & Hamidi, M. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.07.009 · Cited by 78
Miller, T. H., McEneff, G. L., Brown, R. J., Owen, S. F., Bury, N. R., & Barron, L. (2014) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2014.12.034 · Cited by 80
Manasfi, R., Brienza, M., Aït-Mouheb, N., Montemurro, N., Pérez, S., & Chirón, S. (2020) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2020.142742 · Cited by 67
Filter-cultured ARPE-19 cells as outer blood–retinal barrier model
Mannermaa, E., Reinisalo, M., Ranta, V., Vellonen, K., Kokki, H., Saarikko, A., Kaarniranta, K., & Urtti, A. O. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.04.001 · Cited by 72
Gill cell culture systems as models for aquatic environmental monitoring
Bury, N. R., Schnell, S., & Högstrand, C. (2014) · Journal of Experimental Biology · doi:10.1242/jeb.095430 · Cited by 70
“A number of mammalian studies have identified active transport of drugs across membranes (Sugano et al., 2010; Dobson and Kell, 2008) and indicated that the uptake rate of all compounds will be a summation of that via passive diffusion or carrier-mediated processes.”
BackgroundAn Overview of Cell-Based Assay Platforms for the Solute Carrier Family of Transporters
Dvorak, V., Wiedmer, T., Ingles-Prieto, A., Altermatt, P., Batoulis, H., Bärenz, F., Bender, E., Digles, D., Dürrenberger, F., Heitman, L. H., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.722889 · Cited by 67
“In addition, increasing amount of evidence suggests that most drugs and steroid hormones may require transporters to enter cells (Dobson and Kell, 2008; Okamoto et al., 2018; Girardi et al., 2020a).”
BackgroundSelf-citationThe potential therapeutic effects of ergothioneine in pre-eclampsia
Kerley, R. N., McCarthy, C., Kell, D. B., & Kenny, L. C. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.12.030 · Cited by 67
Self-citationEfficient discovery of anti-inflammatory small-molecule combinations using evolutionary computing
Small, B. G., McColl, B. W., Allmendinger, R., Pahle, J., López‐Castejón, G., Rothwell, N. J., Knowles, J. D., Mendes, P., Brough, D., & Kell, D. B. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.689 · Cited by 78
Self-citationLeung, S. S. F., Sindhikara, D., & Jacobson, M. P. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00005 · Cited by 67
Immunological Tolerance, Pregnancy, and Preeclampsia: The Roles of Semen Microbes and the Father†
Kenny, L. C., & Kell, D. B. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2017.00239 · Cited by 74
Self-citationSoars, M. G., Webborn, P. J. H., & Riley, R. J. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800246x · Cited by 70
Lancaster, C. S., Sprowl, J. A., Walker, A. L., Hu, S., Gibson, A. A., & Sparreboom, A. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0926 · Cited by 66
“tics are transported across membranes via passive diffusion at a rate related to their hydrophobicity (2).”
Wendt, M. D. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.9.1123 · Cited by 67
“Existing dogma may favor active transport, and this is possible given the hundreds of transporters already identified and their cataloged behavior toward pharmaceutical drugs [85] .”
BackgroundO’Hagan, S., & Kell, D. B. (2015) · PeerJ · doi:10.7717/peerj.1405 · Cited by 69
Self-citationEfflux and uptake transporters as determinants of statin response
Rodrigues, A. C. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425251003713519 · Cited by 64
“Organic anion transporting polypeptides (OATP/SLCO) are a family of the SLC superfamily of plasma membrane transport proteins that mediate active sodium-independent cellular influx of a variety of amphipathic compounds [5].”
BackgroundKramer, W. (2011) · Biological Chemistry · doi:10.1515/bc.2011.017 · Cited by 64
Poirier, A., Funk, C., Scherrmann, J.-M., & Lavé, T. (2009) · Molecular Pharmaceutics · doi:10.1021/mp8002495 · Cited by 61
Enhanced Therapeutic Efficacy of iRGD-Conjugated Crosslinked Multilayer Liposomes for Drug Delivery
Liu, Y., Ji, M. K., Wong, M. K. K., Joo, K., & Wang, P. (2013) · BioMed Research International · doi:10.1155/2013/378380 · Cited by 65
“Endocytosis is known as one of the main entry mechanisms for various nanoscale drug carriers [22, 23].”
In vitro screening of nanomedicines through the blood brain barrier: A critical review
Aparicio-Blanco, J., Martín‐Sabroso, C., & Torres‐Suárez, A. I. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.06.051 · Cited by 68
“Consequently, most hydrophilic molecules and macromolecules must go through the brain endothelium transcellularly by any of the following pathways: passive diffusion, facilitated diffusion [51] or endo-/transcytosis, (which can be triggered either by ligandreceptor binding or by electrostatic interactions).”
BackgroundRomero‐Canelón, I., Pizarro, A. M., Habtemariam, A., & Sadler, P. J. (2012) · Metallomics · doi:10.1039/c2mt20189e · Cited by 62
Kell, D. B., Potgieter, M., & Pretorius, E. (2015) · F1000Research · doi:10.12688/f1000research.6709.2 · Cited by 67
Self-citationFortuna, A. C., Alves, G., Falcão, A. C., & Soares-da-Silva, P. (2012) · Epilepsia · doi:10.1111/j.1528-1167.2012.03409.x · Cited by 70
“P-glycoprotein (P-gp), a member of the adenosine triphosphate–binding cassette (ABC) transporter superfamily (Doherty & Charman, 2002; Dobson & Kell, 2008), is expressed on the apical membrane of the polarized intestinal epithelium and it clearly affects the rate and Fa of clinical relevant drugs…”
BackgroundMembrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Liu, J. J., Lu, J., & McKeage, M. J. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912803251199 · Cited by 68
“However, one of the current challenges in this field is to substantiate the in vivo role of drug transporters in the pharmacokinetics of platinum drugs in the face of complex co-expression of uptake and efflux transporters and their varying abundances, redundancies, overlapping substrate specificities, functional poly…”
BackgroundStott, L. C., Schnell, S., Högstrand, C., Owen, S. F., & Bury, N. R. (2014) · Aquatic Toxicology · doi:10.1016/j.aquatox.2014.12.007 · Cited by 60
Lee, S., Song, Y., Hong, B. J., MacRenaris, K. W., Mastarone, D. J., O’Halloran, T. V., Meade, T. J., & Nguyen, S. T. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201004867 · Cited by 63
Transporters: Importance in Drug Absorption, Distribution, and Removal
Rüssel, F. G. M. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0840-7_2 · Cited by 59
“There is growing evidence to suggest that it is the rule rather than the exception that a given drug will interact with a set of membrane transporters at some point of its disposition in the body (Dobson and Kell, 2008).”
BackgroundKumal, R. R., Nguyenhuu, H., Winter, J. E., McCarley, R. L., & Haber, L. H. (2017) · The Journal of Physical Chemistry C · doi:10.1021/acs.jpcc.7b05058 · Cited by 59
Kozlovskaya, V., Liu, F., Xue, B., Ahmad, F., Alford, A., Saeed, M. F., & Kharlampieva, E. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b00687 · Cited by 59
Intracellular distribution of nontargeted quantum dots after natural uptake and microinjection
Damalakienė, L., Karabanovas, V., Valius, M., Rotomskis, R., & Bagdonas (2013) · International Journal of Nanomedicine · doi:10.2147/ijn.s39658 · Cited by 58
“through the intact cell plasma membrane is negligible, even if the size of biologically inert quantum dots implies that they could enter the cell via pore defects.(36) Despite time-related differences, the distribution of nontargeted quantum dots followed similar accumulation stages and morphological phases in the dif…”
Kell, D. B. (2012) · BioEssays · doi:10.1002/bies.201100144 · Cited by 70
Self-citationMing, X., & Thakker, D. R. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.08.029 · Cited by 56
Biedermann, F., Ghale, G., Hennig, A., & Nau, W. M. (2020) · Communications Biology · doi:10.1038/s42003-020-1108-9 · Cited by 59
Kell, D. B., Samanta, S., & Swainston, N. (2020) · Biochemical Journal · doi:10.1042/bcj20200781 · Cited by 65
Self-citationKimoto, E., Mathialagan, S., Tylaska, L. A., Niosi, M., Lin, J., Carlo, A. A., Tess, D. A., & Varma, M. V. S. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.252049 · Cited by 58
“Whereas cell membrane composition difference across the systems may contribute to the observed poor correlation (Simons and Ikonen, 1997), the role of uptake transporters cannot be ruled out in the transcellular permeability model (Dobson and Kell, 2008; Ahlin et al., 2009; Kell et al., 2011).”
BackgroundSignificance of Lipid Composition in a Blood-Brain Barrier–Mimetic PAMPA Assay
Campbell, S. D., Regina, K. J., & Kharasch, E. D. (2014) · SLAS Discovery · doi:10.1177/1087057113497981 · Cited by 53
An overview of recent development in therapeutic drug carrier system using carbon nanotubes
Saleemi, M. A., Kong, Y. L., Yong, P. V. C., & Wong, E. H. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101855 · Cited by 58
Kell, D. B. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.10.005 · Cited by 58
Self-citationRamu, V., Gill, M. R., Jarman, P. J., Turton, D., Thomas, J. A., Das, A., & Smythe, C. (2015) · Chemistry - A European Journal · doi:10.1002/chem.201500561 · Cited by 59
Contardo‐Jara, V., Pflugmacher, S., Nützmann, G., Kloas, W., & Wiegand, C. (2010) · Environmental Pollution · doi:10.1016/j.envpol.2010.03.012 · Cited by 62
“If metoprolol is taken up actively, and thus carriermediated such as propranolol (Dobson and Kell, 2008), the decreasing BCF with increasing metoprolol concentrations suggests a regulation of the uptake due to a competition for binding sites at the carrier itself, hence an inhibition of influx.”
BackgroundGenetics and iron in the systems biology of Parkinson’s disease and some related disorders
Funke, C., Schneider, S. A., Berg, D., & Kell, D. B. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.11.015 · Cited by 54
“There are also issues connected with getting such drugs to their actual sites of action (Dobson and Kell, 2008; Kell et al., 2011, 2012).”
Self-citationGualdrón‐López, M., Brennand, A., Avilán, L., & Michels, P. A. M. (2012) · Parasitology · doi:10.1017/s0031182012001278 · Cited by 59
“…recent analyses suggest that even most known hydrophobic drugs do not reach their intracellular targets by passively permeating through the lipid-bilayer membranes of cells, but are internalized by transporters (Dobson and Kell, 2008; Dobson et al. 2009; Lanthaler et al. 2011; Kell et al. 2011).”
BackgroundRuark, C. D., Hack, C. E., Robinson, P. J., Mahle, D. A., & Gearhart, J. M. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24011 · Cited by 57
Cocucci, E., Kim, J., Bai, Y., & Pabla, N. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.545 · Cited by 57
Nuclear Export Mediated Regulation of MicroRNAs: Potential Target for Drug Intervention
Muqbil, I., Bao, B., Abou‐Samra, A., Mohammad, R. M., & Azmi, A. S. (2013) · Current Drug Targets · doi:10.2174/1389450111314100002 · Cited by 56
“Nucleocytoplasmic shuttling of biomolecules (small RNAs, proteins) and drugs occurs through nuclear pore complexes, which penetrate the nuclear envelope and permit passage of material either by passive diffusion [14] or facilitated (carrier mediated) translocation [15].”
BackgroundDrug Transporters in the Central Nervous System
Stieger, B., & Gao, B. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0241-y · Cited by 61
“plasma membranes, transport systems are needed [4, 5].”
BackgroundAmino Acid Transporters as Disease Modifiers and Drug Targets
Bröer, S. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218755629 · Cited by 58
Žiberna, L., Lunder, M., Tramer, F., Drevenšek, G., & Passamonti, S. (2011) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2011.02.005 · Cited by 58
“In the last hypothesis, translocation of flavonoids through the cell plasma membrane must occur via specific transport proteins [7].”
BackgroundBioavailability of Flavonoids: The Role of Cell Membrane Transporters
Čvorović, J., Žiberna, L., Fornasaro, S., Tramer, F., & Passamonti, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813006-3.00022-2 · Cited by 59
Cowgill, L. D., & Langston, C. E. (2011) · Wiley eBooks · doi:10.1002/9781118785546.ch49 · Cited by 78
Effect of Cholesterol on Cellular Uptake of Cancer Drugs Pirarubicin and Ellipticine
Zhang, L., Bennett, W. F., Zheng, T., Ouyang, P.-K., Ouyang, X., Qiu, X., Luo, A., Karttunen, M., & Chen, P. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5b12337 · Cited by 50
Contribution of Abcc4-Mediated Gastric Transport to the Absorption and Efficacy of Dasatinib
Furmanski, B. D., Hu, S., Fujita, K., Li, L., Gibson, A. A., Janke, L. J., Williams, R. T., Schuetz, J. D., Sparreboom, A., & Baker, S. D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0980 · Cited by 50
“However, mounting recent evidence points to drug transport proteins playing a more significant role in the transfer of small molecules across cellular membranes than held previously (41).”
A CRISPRi/a screening platform to study cellular nutrient transport in diverse microenvironments
Chidley, C., Darnell, A. M., Gaudio, B. L., Lien, E. C., Barbeau, A. M., Heiden, M. G. V., & Sorger, P. K. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01402-1 · Cited by 52
Seifter, J. L. (2019) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2019.04.006 · Cited by 59
Kell, D. B. (2021) · Molecules · doi:10.3390/molecules26185629 · Cited by 52
Self-citationZhang, S., Thompson, J. P., Xia, J., Bogetti, A. T., York, F., Skillman, A. G., Chong, L. T., & LeBard, D. N. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01540 · Cited by 51
Recent Experimental Developments in Studying Passive Membrane Transport of Drug Molecules
Gh., M. S. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00009 · Cited by 51
Wilhelm, M. J., Sheffield, J. B., Gonella, G., Wu, Y., Spahr, C., Zeng, J., Xu, B., & Dai, H. (2014) · Chemical Physics Letters · doi:10.1016/j.cplett.2014.05.009 · Cited by 45
Enantiomeric Cyclic Peptides with Different Caco‐2 Permeability Suggest Carrier‐Mediated Transport
Marelli, U. K., Bezençon, J., Puig, E., Ernst, B., & Kessler, H. (2015) · Chemistry – A European Journal · doi:10.1002/chem.201501270 · Cited by 45
Kalxdorf, M., Gade, S., Eberl, H. C., & Bantscheff, M. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.063859 · Cited by 46
“jacked for transporter-mediated drug uptake (12, 13, 16).”
BackgroundDrug delivery: A process governed by species-specific lipophilicities
Mazák, K., & Noszál, B. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.05.017 · Cited by 44
The Efflux Pump Inhibitor Timcodar Improves the Potency of Antimycobacterial Agents
Grossman, T. H., Shoen, C. M., Jones, S. M., Jones, P. L., Cynamon, M. H., & Locher, C. P. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04271-14 · Cited by 46
“360 We studied the pharmacokinetic parameters of selected anti361 mycobacterial agents, including RIF, with and without TIM because it is known 362 that transporters are involved in efflux mechanisms that can promote or limit the 363 absorption of drugs in the gut and penetration into tissues (24, 28, 33, 34).”
BackgroundMultiscale modelling of drug transport and metabolism in liver spheroids
Leedale, J., Kyffin, J. A., Harding, A. L., Colley, H. E., Murdoch, C., Sharma, P., Williams, D. P., Webb, S. D., & Bearon, R. N. (2020) · Interface Focus · doi:10.1098/rsfs.2019.0041 · Cited by 52
Holden, L., Burke, C. S., Cullinane, D., & Keyes, T. E. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00049g · Cited by 49
How do antimalarial drugs reach their intracellular targets?
Basore, K., Cheng, Y., Kushwaha, A. K., Nguyen, S. T., & Desai, S. A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00091 · Cited by 44
“Specialty section: This article was submitted to Drug Metabolism and Transport, a section of the journal Frontiers in Pharmacology Received: 29 January 2015 Accepted: 14 April 2015 Published: 05 May 2015 Citation: Basore K, Cheng Y, Kushwaha AK, Nguyen ST and Desai SA (2015) How do antimalarial drugs reach their intra…”
BackgroundMolecular Property Filters Describing Pharmacokinetics and Drug Binding
García‐Sosa, A. T., Maran, U., & Hetényi, C. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712799945021 · Cited by 48
“characteristics also influence drug-likeness [7].”
BackgroundMukkamala, D., No, J. H., Cass, L. M., Chang, T.-K., & Oldfield, E. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8009074 · Cited by 44
Prodrug Approach as a Strategy to Enhance Drug Permeability
de Souza, M. M., Gini, A. L. R., Moura, J. A., Scarim, C. B., Chin, C. M., & dos Santos, J. L. (2025) · Pharmaceuticals · doi:10.3390/ph18030297 · Cited by 55
“Active transport is facilitated by transport proteins that utilize energy (e.g., adenosine triphosphate (ATP) hydrolysis) to assist compounds in crossing the membrane, with the drug’s affinity for the transport protein playing a critical role in this process [21].”
Fischer, F. C., Abele, C., Droge, S. T. J., Henneberger, L., König, M., Schlichting, R., Scholz, S., & Escher, B. I. (2018) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.8b00019 · Cited by 46
Hussein, H. A., Mohamad, H., Ghazaly, M. M., Laith, A. A., & Abdullah, M. A. (2019) · Journal of Applied Phycology · doi:10.1007/s10811-019-01905-7 · Cited by 49
“NPs can regulate the solubility and chemical stability of anti-cancer drugs by enveloping the compound in a hydrophilic nanocarrier or co-application of natural compounds with nanomedicine (Dobson and Kell 2008; Gul-e-Saba and Abdullah 2015; Wicki et al. 2015).”
BackgroundYun, Y. E., & Edginton, A. N. (2013) · Xenobiotica · doi:10.3109/00498254.2013.770182 · Cited by 47
“The presented approach assumes that the tissue partitioning is driven by the passive transport of a molecule into tissues, even though one group of researchers has questioned the validity of assuming passive diffusion for any drug (Dobson & Kell, 2008).”
BackgroundLi, Y., Zhou, Z., Chen, S., Pang, X., Wu, C., Li, H., & Zhang, Y. (2023) · Analytica Chimica Acta · doi:10.1016/j.aca.2023.340967 · Cited by 42
Muelas, M. W., Roberts, I., Mughal, F., O’Hagan, S., Day, P. J., & Kell, D. B. (2020) · Metabolomics · doi:10.1007/s11306-020-01725-8 · Cited by 43
Self-citationAn analysis of a ‘community-driven’ reconstruction of the human metabolic network
Swainston, N., Mendes, P., & Kell, D. B. (2013) · Metabolomics · doi:10.1007/s11306-013-0564-3 · Cited by 45
Self-citationKnowledge needed about the exchange physiology of the placenta
Sibley, C. P., Brownbill, P., Glazier, J. D., & Greenwood, S. L. (2018) · Placenta · doi:10.1016/j.placenta.2018.01.006 · Cited by 43
Quantifying the impact of transporters on cellular drug permeability
Matsson, P., Fenu, L. A., Lundquist, P., Wiśniewski, J. R., Kansy, M., & Artursson, P. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.02.009 · Cited by 44
Chemical Reactions in Living Systems
Schauenburg, D., & Weil, T. (2023) · Advanced Science · doi:10.1002/advs.202303396 · Cited by 42
Dynamic Cellular Uptake of Mixed-Monolayer Protected Nanoparticles
Carney, R. P., Carney, T. M., Mueller, M., & Stellacci, F. (2012) · Biointerphases · doi:10.1007/s13758-011-0017-3 · Cited by 40
Jindal, S., Yang, L., Day, P. J., & Kell, D. B. (2019) · BMC Microbiology · doi:10.1186/s12866-019-1561-0 · Cited by 42
“up by cells, it is reasonable that influx transporters were exploited to get them there in the first place [24-27].”
BackgroundSelf-citationParameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary Report
Pepin, X. J. H., Arora, S., Borges, L. N., Cano-Vega, M. A., Carducci, T. M., Chatterjee, P., Chen, G., Cristofoletti, R., Dallmann, A., Delvadia, P. R., et al. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00526 · Cited by 42
Cellular Uptake of the Atypical Antipsychotic Clozapine Is a Carrier-Mediated Process
Dickens, D., Rädisch, S., Chiduza, G. N., Giannoudis, A., Cross, M. J., Malik, H., Schaeffeler, E., Sison-Young, R. L. C., Wilkinson, E. L., Goldring, C. E., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00547 · Cited by 39
Roles of Hepatic Drug Transporters in Drug Disposition and Liver Toxicity
Pan, G. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-7647-4_6 · Cited by 40
Theoretical considerations for thresholds in chemical carcinogenesis
Thomas, A. D., Fahrer, J., Johnson, G. E., & Kaina, B. (2015) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2015.05.001 · Cited by 44
Thalhammer (2009) · Oncology Reports · doi:10.3892/or_00000591 · Cited by 38
Kunjiappan, S., Theivendren, P., Saravanan, G., Pavadai, P., Baskararaj, S., Murugesan, S., Arunachalam, S., Babkiewicz, E., Jeyakumar, A., & Muthulakshmi, L. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666190702145609 · Cited by 40
Flaten, G. E., Kottra, G., Stensen, W., Isaksen, G. V., Karstad, R., Svendsen, J. S. M., Daniel, H., & Svenson, J. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm1015704 · Cited by 43
Chan, T., Zhu, L., Madigan, M. C., Wang, K., Shen, W., Gillies, M. C., & Zhou, F. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13060 · Cited by 50
“Passive diffusion of molecules across biological membranes driven by a concentration gradient occurs for many substances; however, active uptake of molecules via membrane proteins, particularly transporters, may be more common than is usually assumed (Dobson and Kell, 2008).”
BackgroundO’Hagan, S., & Kell, D. B. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00105 · Cited by 39
“…et al., 2015), motivated by the recognition that drugs do, and probably have to, hitchhike on metabolite transporters in order to get into cells (Dobson and Kell, 2008; Dobson et al., 2009a,b; Giacomini et al., 2010; Kell et al., 2011, 2013, 2015; Kell, 2013, 2015; Kell and Goodacre, 2014;…”
BackgroundSelf-citationTherapeutic applications of lipoic acid: a patent review (2011 – 2014)
Koufaki, M. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.937425 · Cited by 40
“It is known that cellular uptake of LA is mediated by the sodium-dependent multivitamin transporter, SMVT, a system that could be targeted for delivering drugs with poor permeability [92,93].”
BackgroundLiu, Y., Fang, J., Joo, K. I., Wong, M. K. K., & Wang, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110611 · Cited by 37
“Moreover, these nanoparticles can enter cancer cells through endocytosis in a manner independent of the P-gp pathway, thereby enhancing cellular accumulation of therapeutics [25,26,27].”
BackgroundKell, D. B. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.44 · Cited by 37
Self-citationTse, C. H., Comer, J. R., Chu, S. K. S., Wang, Y., & Chipot, C. J. (2019) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.9b00022 · Cited by 37
Mazák, K., & Noszál, B. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.03.053 · Cited by 37
Alves, L. D. F., Moore, J. B., & Kell, D. B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25169082 · Cited by 43
Self-citationcis‐Peptide Bonds: A Key for Intestinal Permeability of Peptides?
Marelli, U. K., Ovadia, O., Frank, A. O., Chatterjee, J., Gilon, C., Hoffman, A., & Kessler, H. (2015) · Chemistry - A European Journal · doi:10.1002/chem.201501600 · Cited by 38
Uptake Carriers and Oncology Drug Safety
Sprowl, J. A., & Sparreboom, A. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.055806 · Cited by 37
“In fact, the contribution of transporter-mediated uptake of xenobiotics is now believed to be the predominant mechanism of intracellular accumulation (Dobson and Kell, 2008).”
BackgroundpH plays a role in the mode of action of trimethoprim on Escherichia coli
Alrabiah, H. K., Allwood, J. W., Correa, E. S., Yun Xu, A., & Goodacre, R. (2018) · PLoS ONE · doi:10.1371/journal.pone.0200272 · Cited by 38
Effects of Binary Mixtures and Transpiration on Accumulation of Pharmaceuticals by Spinach
Nason, S. L., Miller, E. L., Karthikeyan, K. G., & Pedersen, J. A. (2019) · Environmental Science & Technology · doi:10.1021/acs.est.8b05515 · Cited by 38
Salcedo-Sora, J. E., & Kell, D. B. (2020) · Antibiotics · doi:10.3390/antibiotics9080508 · Cited by 35
Self-citationKikuchi, R., McCown, M. F., Olson, P., Tateno, C., Morikawa, Y., Katoh, Y., Bourdet, D. L., Monshouwer, M., & Fretland, A. J. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.031732 · Cited by 35
“Cumulative evidence suggests that members of the solute carrier (SLC) and ATP-binding cassette (ABC) transporters are expressed on either sinusoidal or canalicular membrane of the hepatocytes where they are responsible for the sinusoidal uptake and bile canalicular efflux of a diverse set of compounds (Chandra and Bro…”
BackgroundModeling the effects of commonly used drugs on human metabolism
Sahoo, S., Haraldsdóttir, H. S., Fleming, R. M. T., & Thiele, I. (2014) · FEBS Journal · doi:10.1111/febs.13128 · Cited by 38
Metadata
- Authors
- Dobson, P. D., & Kell, D. B.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Kell, Douglas B.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2008-03
- Volume
- 7
- Issue
- 3
- Pages
- 205-220
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2157619122
- Cited by
- 475
- References
- 265
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 20 · 2023: 19 · 2022: 18 · 2021: 24 · 2020: 27 · 2019: 20 · 2018: 17 · 2017: 28 · 2016: 36 · 2015: 43 · 2014: 42 · 2013: 29 · 2012: 36
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Funders
- Royal Society
- Wolfson Foundation
- Engineering and Physical Sciences Research Council
- Biotechnology and Biological Sciences Research Council (747/1, BB/D007)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- passive diffusion, lipophilicity, membrane transporters, drug discovery, drug development
- MeSH terms
- Animals, Biological Transport, Cell Membrane, Cell Membrane Permeability, Pharmaceutical Preparations, Humans, Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.